Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer.

PURPOSE To present nomograms providing estimates of prostate-specific antigen (PSA) failure-free survival after radical prostatectomy (RP) or external-beam radiation therapy (RT) for men diagnosed during the PSA era with clinically localized disease. PATIENTS AND METHODS A Cox regression multivariable analysis was used to determine the prognostic significance of the pretreatment PSA level, 1992 American Joint Committee on Cancer (AJCC) clinical stage, and biopsy Gleason score in predicting the time to posttherapy PSA failure in 1,654 men with T1c,2 prostate cancer managed with either RP or RT. RESULTS Pretherapy PSA, AJCC clinical stage, and biopsy Gleason score were independent predictors (P < .0001) of time to posttherapy PSA failure in patients managed with either RP or RT. Two-year PSA failure rates derived from the Cox regression model and bootstrap estimates of the 95% confidence intervals are presented in the format of a nomogram stratified by the pretreatment PSA, AJCC clinical stage, biopsy Gleason score, and local treatment modality. CONCLUSION Men at high risk (> 50%) for early (< or = 2 years) PSA failure could be identified on the basis of the type of local therapy received and the clinical information obtained as part of the routine work-up for localized prostate cancer. Selection of these men for trials evaluating adjuvant systemic and improved local therapies may be justified.

[1]  A. D'Amico,et al.  The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. , 1998, The Journal of urology.

[2]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[3]  M. Loda,et al.  Low p27 expression predicts poor disease-free survival in patients with prostate cancer. , 1998, The Journal of urology.

[4]  H. Frierson,et al.  Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate , 1997, Cancer.

[5]  A. D'Amico,et al.  Outcome based staging for clinically localized adenocarcinoma of the prostate. , 1997, The Journal of urology.

[6]  S. Ménard,et al.  Independent prognostic value of the 67-kd laminin receptor in human prostate cancer. , 1997, Journal of the National Cancer Institute.

[7]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[8]  A. D'Amico,et al.  Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Kahn,et al.  A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma , 1997, Cancer.

[10]  D. Bostwick,et al.  Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. , 1996, The Journal of urology.

[11]  J. Oesterling,et al.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. , 1995, The Journal of urology.

[12]  T. Schultheiss,et al.  Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. , 1995, The Journal of urology.

[13]  A Pollack,et al.  Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. , 1995, International journal of radiation oncology, biology, physics.

[14]  F. Marshall,et al.  Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. , 1995, Urology.

[15]  M. Hunt,et al.  Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Partin,et al.  Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. , 1994, The Journal of urology.

[17]  A. Zietman,et al.  Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. , 1994, Urology.

[18]  A. Partin,et al.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. , 1994, Urology.

[19]  A. Zietman,et al.  Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. , 1994, The Journal of urology.

[20]  S. Cha,et al.  Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Schemper,et al.  The relative importance of prognostic factors in studies of survival. , 1991, Statistics in medicine.

[22]  D. Gleason,et al.  Histologic Grading and Staging of Prostatic Carcinoma , 1981 .

[23]  J. Cadeddu,et al.  Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. , 1998, The Journal of urology.

[24]  M. Kattan,et al.  Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. , 1998, Cancer.

[25]  G E Hanks,et al.  Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D.,et al.  Regression Models and Life-Tables , 2022 .